The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).

Phase 1 Not yet recruiting 3 enrolled XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

A Phase I Study to Assess the Safety, Tolerability and Efficacy of dopaminergic neural progenitor cells (XS411CN cell injection) for the treatment of multiple system atrophy Parkinsonian variant (MSA-P).

Timeline

Start: 2026-06-15
Primary completion: 2026-08-30
Completion: 2028-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	XS411CN	Cell therapy	5e+06 cells	Other

The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).

Summary

Timeline

Drugs

Indications